Here’s what I’ve noticed after years of working with pharma data teams: everyone talks about needing “better data,” but what they really mean is they need data they can actually use. Right now. Without spending six months on data engineering.
Look, if you’re a Data Scientist trying to train ML models on healthcare data, or a Biostatistician preparing an HTA submission, or a Clinical Operations Lead designing your next trial—you’re facing the same fundamental problem. The data you need is either locked behind privacy walls, fragmented across incompatible systems, or so incomplete it’s basically useless for serious analysis.
Privacy-compliant, model-ready enriched healthcare datasets solve this. Not eventually. Not theoretically. They solve it now by giving you access to aggregated real-world data from multiple sources and synthetic datasets that mirror real patient populations—without the GDPR nightmares, without the data engineering bottleneck, and without compromising on statistical validity.
Why Traditional Healthcare Data Approaches Keep Failing Pharma Teams
The uncomfortable truth about pharma data enrichment is that most companies are still trying to solve 2025 problems with 2015 approaches.
You’re either working with raw claims data that requires months of cleaning and harmonization, or you’re dealing with single-source EHR data that’s so limited in scope it can’t answer your actual research questions. And if you’re trying to work with rare disease populations or underrepresented demographic groups? Good luck finding enough real patient records that aren’t restricted by privacy regulations.
What actually works is a fundamentally different approach: health dataset enrichment that combines aggregated multi-source real-world data with validated synthetic augmentation.
Let me be specific about what this means in practice. Instead of spending 4-6 months integrating claims data from three different insurers, then another 2 months cleaning it, then discovering you still don’t have enough rare disease patients… you get analysis-ready datasets that are already harmonized, validated, and enriched with synthetic cohorts where real-world data is scarce.
What Data Scientists and AI-ML Engineers Need to Know About Model-Ready Healthcare Datasets
If you’re building predictive models or training AI on healthcare data, you already know the core challenge: data scarcity kills model performance.
Traditional approaches give you either-or choices. Either you work with limited real-world data and accept poor model generalization, or you try to augment with synthetic data but can’t validate its fidelity. Neither option is acceptable when you’re trying to predict treatment outcomes, identify adverse events early, or optimize clinical trial protocols.
Modern ML-ready insurance data and machine-learning-ready RWD datasets solve this through a three-layer enrichment approach that the Nature Biomedical Engineering 2021 review on synthetic data in ML describes as the current state-of-the-art for healthcare AI applications.
First layer: comprehensive aggregated claims databases covering diverse patient populations across multiple payers and providers. This gives you real-world treatment patterns, outcomes, and healthcare utilization data with longitudinal tracking. Second layer: synthetic data generated using advanced generative adversarial networks (GANs) with differential privacy guarantees—not just random noise, but statistically valid patient cohorts that preserve complex correlations in the original data. Third layer: feature engineering and standardization so you’re working with feature-ready medical datasets instead of raw tables you need to transform yourself.
The npj Digital Medicine 2023 paper on synthetic data in healthcare demonstrates how this approach addresses the critical ML challenges: bias correction through balanced synthetic cohorts, privacy preservation through mathematically provable anonymization, and dataset augmentation that maintains clinical validity.
What this means for your models: faster training on larger, more representative datasets. Better generalization because you’re not overfitting to a single data source. And crucially—you can actually deploy these models without worrying that patient privacy lawyers will shut down your entire project.
For Biostatisticians: The Data Quality Standards You Actually Need
Statistical validity isn’t optional in pharma. You know this better than anyone.
The challenge with aggregated and enriched medical claims data has always been harmonization across sources with different coding systems, different completeness levels, and different administrative focuses. Insurance claims aren’t designed for research—they’re designed for reimbursement. That creates systematic biases and missing data patterns that can invalidate your analyses if you’re not careful.
High-quality validated enriched insurance data addresses this through rigorous standardization processes. ICD-10 diagnosis codes, ATC classification for medications, standardized procedural codes—all mapped to common data models and validated against reference populations. The FDA’s 2024 guidance on assessing EHR and claims data provides the framework for data quality assessment that enriched datasets should meet.
For rare disease work where sample sizes are inherently limited, synthetic data augmentation using validated generative models provides the statistical power you need. But—and this is critical—the synthetic cohorts must preserve not just univariate distributions but the multivariate correlation structure of real patient populations. The PLOS ONE 2023 narrative review on synthetic health data discusses validation approaches including comparing synthetic vs. real data on key statistical measures, clinical plausibility checks, and utility testing for specific analytical tasks.
Clinical Trial Optimization: External Controls and Synthetic Arms That Regulators Actually Accept
Clinical trial design is being transformed by enriched RWD datasets and synthetic data—but only when it’s done right.
The promise has always been there: use external real-world data to create control arms, reducing trial costs and enrollment requirements. Use synthetic patients to augment small populations in rare diseases. The reality? Most attempts fail regulatory scrutiny because the data quality isn’t sufficient or the methodology isn’t transparent enough.
What’s actually working now is a more sophisticated approach that the 2020 Therapeutic Innovation & Regulatory Science primer on synthetic and external controls describes in detail. You need linked claims datasets that provide complete longitudinal patient journeys—not just isolated snapshots. You need validation against trial-eligible populations to ensure your external controls actually match your intervention cohort on relevant characteristics.
And here’s what most people miss: the FDA’s evolving framework for synthetic controls isn’t just about having synthetic data. The FDA’s 2023 guidance on RWD and RWE makes clear that regulators want to see comprehensive data on how the external data was selected, how synthetic cohorts were generated and validated, and how potential biases were addressed.
The Nature Communications 2022 case study on Pralsetinib in NSCLC provides a real-world example of how enriched RWD-based synthetic controls can support comparative effectiveness claims—but notice how much methodological rigor went into that work.
For Clinical Operations: Patient Selection and Trial Optimization
Patient recruitment delays are killing trial timelines and budgets. Everyone knows it. But here’s what actually solves it…
Enriched longitudinal healthcare data gives you visibility into real patient populations before you start recruiting. You can analyze treatment patterns, identify sites with high concentrations of trial-eligible patients, and optimize inclusion/exclusion criteria based on what’s actually prevalent in the real world—not what you hoped would be common.
Synthetic data extends this by letting you model different trial scenarios. What if you expand the age range? What if you modify the comorbidity exclusions? You can test these protocol variations on synthetic cohorts that preserve the statistical properties of real patient populations without needing to run actual pilot studies.
Real-World Evidence Generation: HEOR, Market Access, and Payer Negotiations
HEOR teams and Market Access professionals face a specific challenge that’s getting harder: payers want local, real-world evidence demonstrating value… and they want it before they’ll consider reimbursement.
Generic RWE studies don’t cut it anymore. You need RWE analytics databases with the geographic and demographic specificity that matches your payer’s population. You need longitudinal data showing complete patient journeys—not just treatment initiation but outcomes, healthcare utilization, and costs over time.
The FDA’s ongoing guidance on non-interventional studies describes how enriched aggregated RWD supports effectiveness and safety evidence generation beyond traditional clinical trials. But the European perspective is different—HTA bodies like NICE in the UK or HAS in France have specific requirements for data quality, relevance, and transferability.
Multi-payer enriched datasets aggregated across multiple insurance sources provide the comprehensive view you need. Treatment patterns in diverse populations. Outcomes in real-world settings with comorbidities and concomitant medications that clinical trials excluded. Cost data that reflects actual healthcare utilization—not protocol-driven trial costs.
For Health Economists: Cost-Effectiveness Modeling with Real-World Data
Budget impact models and cost-effectiveness analyses require data inputs that most pharma companies struggle to obtain: real-world treatment patterns, healthcare resource utilization, and outcomes in representative populations.
Healthcare utilization datasets provide exactly this—inpatient admissions, outpatient visits, emergency department use, procedures, and associated costs. When you’re building Markov models or discrete event simulations for HTA submissions, having real-world transition probabilities and cost parameters beats expert opinion or literature estimates every time.
Synthetic data augmentation helps when you need to model long-term outcomes beyond what’s available in current claims databases, or when you’re working with new therapeutic areas where limited real-world data exists yet.
Privacy, Compliance, and Data Quality: The Technical Framework That Actually Matters
Let’s talk about the thing that kills most healthcare data projects: privacy and compliance concerns.
GDPR in Europe. HIPAA in the US. Each jurisdiction has specific requirements for how patient data can be used, shared, and stored. And pharma companies are rightfully paranoid about getting this wrong—one privacy breach can destroy your reputation and result in massive fines.
This is where GDPR-compliant data enrichment and anonymized enriched claims databases become essential infrastructure rather than nice-to-have features.
The technical distinction matters here: de-identification, anonymization, and pseudonymization aren’t the same thing legally or technically. True anonymization—where re-identification is mathematically impossible—provides much stronger legal protection under GDPR Article 9. The npj Digital Medicine 2025 paper on regulatory perspectives for synthetic health data privacy analyzes how different regulatory frameworks (UK, Singapore, Korea) approach privacy guarantees for synthetic data specifically.
Synthetic enriched health datasets offer something even better: mathematically provable privacy through differential privacy techniques. The Frontiers in Digital Health 2025 study on synthetic data for rare disease research demonstrates how synthetic data generation can accelerate research while maintaining HIPAA and GDPR compliance—the synthetic patients aren’t derived from any real individual, they’re generated from learned statistical distributions.
Data Quality and Validation Standards
Privacy compliance is necessary but not sufficient. Your data also needs to be… you know, actually correct.
Curated claims databases and cleaned and enriched health datasets should meet rigorous quality standards: completeness checks (what percentage of records have all required fields?), consistency validation (do diagnosis codes align with prescribed treatments?), temporal coherence (do event sequences make clinical sense?), and validation against external benchmarks like national health statistics.
The CPT: Pharmacometrics & Systems Pharmacology 2025 article on synthetic data in drug development discusses FDA and EMA perspectives on defining data quality standards for synthetic data specifically—including fidelity metrics comparing synthetic to real data distributions and utility testing for specific analytical tasks.
Breaking Down Data Silos: Integrated Multi-Source Healthcare Datasets
One of the biggest challenges in healthcare analytics—and honestly, one that doesn’t get talked about enough—is that valuable data lives in completely separate silos.
Claims data from insurers. Electronic health records from hospital systems. Pharmacy dispensing data. Lab results. Patient-reported outcomes. Each source provides a partial view of the patient journey, but integrating them is technically complex and often legally restricted.
Cross-provider linked insurance databases and unified healthcare data repositories solve this through sophisticated linkage methodologies that preserve privacy while creating comprehensive patient-level views. You’re not just seeing that a patient was prescribed a medication—you’re seeing the diagnosis that led to the prescription, the lab results that prompted the diagnosis, the subsequent healthcare utilization, and the long-term outcomes.
This longitudinal integration is what enables meaningful real-world evidence. Treatment effectiveness isn’t just “did the patient fill the prescription?”—it’s “did the patient achieve clinical outcomes, and at what cost in terms of healthcare resource utilization?”
For Data Science Teams: Integration and Pipeline Efficiency
Structured enriched healthcare databases and harmonized healthcare datasets eliminate months of data engineering work.
Instead of building custom ETL pipelines for each data source, mapping different coding systems, handling missing data, and creating patient-level linkages—you get analytics-ready health insurance data that’s already been through these processes. Standardized schemas. Consistent formatting. Validated linkages.
The 2023 Machine Learning for Synthetic Data Generation review discusses technical approaches for generating high-quality synthetic healthcare data, including GANs, variational autoencoders, and diffusion models—but the key point for pharma teams is that you shouldn’t need to build these systems yourself.
Addressing the Specific Pain Points Pharma Teams Actually Face
Now here’s the thing. All this technical capability only matters if it solves your actual day-to-day problems.
For Data Scientists and AI-ML Engineers: You need access to large, diverse, high-quality datasets for model training—but privacy restrictions block you from using sensitive patient data directly. You need to overcome bias and incompleteness in real-world data that leads to poor model performance. And you need this without spending six months on data acquisition and integration.
Model-ready anonymized healthcare datasets with synthetic augmentation solve exactly this. You get the volume and diversity needed for robust ML models, with privacy guarantees that let you actually deploy them.
For Biostatisticians: You’re dealing with incomplete, missing, or noisy data in aggregated RWD. You need to harmonize multi-source data for reliable analysis. You’re facing regulatory scrutiny on data quality for submissions. And for rare diseases, you simply don’t have enough patients.
Validated enriched insurance data with rigorous quality controls and synthetic cohort augmentation addresses these challenges directly.
For Clinical Trial Managers: Slow patient recruitment, high costs from data scarcity in trial design, difficulty creating external controls that regulators accept—these are killing your timelines and budgets.
Patient-level insurance datasets with longitudinal tracking enable better site selection, protocol optimization, and creation of validated external control arms that meet regulatory standards.
For RWE Scientists and HEOR Teams: You’re struggling with fragmented, siloed RWD sources that don’t provide complete patient journeys. Data quality issues. Time-consuming cleaning and harmonization. And mistrust in whether synthetic data can generate robust evidence.
Consolidated RWE datasets with transparent synthetic data validation address exactly these concerns.
What Makes Healthcare Data Enrichment Actually Work in Practice
So what separates enriched healthcare datasets that drive real business value from ones that end up being expensive shelfware?
First: comprehensive source aggregation. Single-source data is inherently limited. You need multi-payer coverage, diverse geographic regions, representative demographic distributions. Aggregation across multiple insurers, hospital systems, and pharmacy networks creates the breadth of coverage that makes analyses valid.
Second: rigorous validation processes. This means validation against external benchmarks (national health statistics, disease registries), clinical plausibility checks by medical experts, statistical validation of synthetic cohorts against real populations, and ongoing quality monitoring.
Third: transparent methodology. You need to know exactly how data was collected, how it was anonymized, how sources were integrated, how synthetic data was generated, and what the limitations are. Regulatory bodies and journal reviewers will ask these questions—you need clear answers.
Fourth: fitness for purpose. Not all enriched datasets are suitable for all use cases. Claims data is excellent for healthcare utilization and outcomes but limited for detailed clinical parameters. Synthetic data is valuable for augmentation and scenario modeling but shouldn’t be your only evidence source. Understanding these distinctions matters.
Emerging Applications: AI, Precision Medicine, and Advanced Analytics
Healthcare is rapidly moving toward AI-driven drug discovery, precision medicine approaches, and predictive analytics—and all of these require sophisticated data infrastructure.
ML datasets for healthcare need to support complex AI applications: natural language processing on clinical notes, computer vision for medical imaging, time-series prediction for disease progression, reinforcement learning for treatment optimization.
This requires not just structured healthcare datasets but also enriched unstructured clinical text datasets and high-dimensional medical datasets that capture the full complexity of patient health status.
Synthetic data plays a crucial role here by augmenting limited real-world data for rare conditions, generating diverse patient scenarios for algorithm training, and enabling safe development of AI systems without privacy concerns blocking innovation.
For Bioinformaticians: Genomic and Multi-Modal Data Integration
The future of precision medicine requires integrating claims data with genomic information, biomarkers, and patient-reported outcomes—creating truly multi-modal patient profiles.
This is technically challenging because of the different data types, the privacy sensitivity of genetic information, and the computational demands of working with high-dimensional data. Integrated patient-level datasets that link administrative claims with clinical and molecular data represent the cutting edge of healthcare data enrichment.
Synthetic data augmentation becomes even more valuable here—generating synthetic genomic profiles for rare variants, creating matched synthetic controls for precision medicine trials, and enabling algorithm development without exposing actual patient genetic data.
Getting Started: Practical Steps for Pharma Teams
Honestly, the hardest part of working with enriched healthcare datasets isn’t the technical complexity—it’s figuring out where to start and which approach matches your specific needs.
Here’s what actually works based on what I’ve seen succeed:
Define requirements before evaluating options. Don’t try to build a comprehensive healthcare data platform on day one. Document your coverage needs (geographies, therapeutic areas, patient populations), analytical capabilities (self-service vs. full-service analytics), integration requirements (API access, data formats, compatibility with existing systems), compliance constraints, and budget parameters. Getting clear on requirements prevents expensive do-overs and helps you compare options on dimensions that actually matter.
Understand the landscape dimensions. The enriched healthcare data market includes providers with varying strengths across several key dimensions: data recency (real-time feeds vs. adjudicated claims with lag times), geographic and therapeutic coverage breadth, synthetic data generation methodology and validation rigor, analytical tool sophistication, integration capabilities, and cost models (per-patient licensing vs. subscription vs. project-based). Some providers excel at comprehensive longitudinal coverage while others focus on advanced analytics or specialized therapeutic areas.
Leverage expert guidance for source selection. The gap between understanding what enriched data can do and identifying which specific providers deliver the right combination of capabilities for your use cases is substantial. The claims data landscape includes dozens of vendors offering overlapping but distinct capabilities. Understanding which combination of coverage, analytical tools, validation methodology, and domain expertise matches your specific needs requires deep market knowledge. Expert advisors who understand both pharmaceutical commercialization and the evolving real-world evidence ecosystem can accelerate your path to value while avoiding common pitfalls like coverage gaps, integration challenges, or methodology mismatches.
Assess data quality rigorously. Request validation reports showing how synthetic data was generated and tested. Ask for sample datasets to evaluate schema design, data completeness, and coding consistency. Compare coverage statistics against published benchmarks. Understand limitations explicitly—no dataset is perfect for every use case.
Plan for integration. How will enriched datasets connect to your existing analytics infrastructure? What technical capabilities does your team need? What training is required? The most sophisticated data becomes shelfware if your team can’t effectively query and analyze it.
Address compliance proactively. Get legal and privacy teams involved early. Understand GDPR/HIPAA implications for your specific use cases. Document data handling procedures. Verify that anonymization or synthetic data generation methods meet your regulatory requirements. This prevents projects getting shut down months in.
Pilot before scaling. Start with a focused project to validate that your chosen approach answers your questions and integrates smoothly with your workflows before committing to large-scale licensing agreements. A successful pilot builds organizational confidence and identifies optimization opportunities.
Frequently Asked Questions About Enriched Healthcare Datasets
How is synthetic healthcare data validated to ensure it’s actually useful?
Validation involves multiple approaches: statistical comparison of synthetic vs. real data distributions on key variables, clinical plausibility review by medical experts, utility testing where synthetic data is used for specific analytical tasks and results are compared to analyses on real data, and privacy testing to confirm synthetic records can’t be re-identified. The gold standard is demonstrating that models trained on synthetic data perform comparably to models trained on real data when tested on held-out real datasets.
Can enriched claims data really replace primary data collection for research?
It depends on your research question. For questions about healthcare utilization, treatment patterns, outcomes in real-world settings, and population-level epidemiology—yes, enriched claims data often provides better answers than primary data collection because of the scale and representativeness. For questions requiring detailed clinical information not captured in claims (specific lab values, imaging results, quality of life measures)—no, you’ll need clinical data sources or primary collection.
What’s the difference between anonymized, de-identified, and pseudonymized data legally?
Under GDPR: Anonymized data is data that cannot be re-identified, even theoretically, and is no longer considered personal data (minimal legal restrictions). Pseudonymized data has identifiers replaced with pseudonyms but could potentially be re-identified (still considered personal data, restricted). De-identified data is similar to pseudonymized—identifiers removed but re-identification may be possible with additional information. Under HIPAA: De-identified data meets specific criteria for identifier removal and is not Protected Health Information. The distinction matters because anonymized/de-identified data has fewer legal restrictions.
How quickly can we actually start using enriched datasets?
With truly analysis-ready datasets: days to weeks, not months. You receive structured data in common formats (CSV, Parquet, database tables), with clear data dictionaries, pre-validated and cleaned. Your data science team can immediately begin queries and analyses. Compare this to raw claims data where 3-6 months of data engineering is typical before you can start meaningful analysis.
What therapeutic areas and indications are typically well-covered?
High-prevalence chronic conditions (diabetes, cardiovascular disease, respiratory conditions, mental health) have excellent coverage. Oncology has good coverage for common cancers but may be limited for rare subtypes. Rare diseases depend heavily on prevalence—ultra-rare conditions may need synthetic augmentation. Acute conditions are well-represented. The key is asking about specific coverage statistics for your indication rather than assuming.
How do we demonstrate to regulators that our RWE study using enriched data is valid?
Regulatory acceptance requires: transparent methodology documentation (exactly how data was collected, validated, and analyzed), validation against external benchmarks, clear handling of missing data and potential biases, sensitivity analyses showing results are robust, and alignment with regulatory guidance (FDA’s RWE framework, EMA guidelines). Work with experienced RWE teams who’ve successfully submitted evidence to regulators in your indication.
What’s the typical cost structure for accessing enriched healthcare datasets?
Pricing models vary: per-patient per-data element, flat subscription fees, project-based licensing, or volume-based tiers. Cost depends on data scope (therapeutic areas, time period, patient population), level of enrichment and customization, ongoing access vs. one-time extraction, and additional services (analysis support, custom cohort identification). Expect meaningful investments—but compare to alternatives like running primary data collection studies or building internal data infrastructure.
Can we combine your enriched datasets with our internal proprietary data?
Yes, and this is often where the most valuable insights emerge. Common integration patterns include: linking external claims data to internal clinical trial databases, enriching internal patient registries with broader population context, combining internal sales data with external treatment pattern data. The technical approach depends on whether direct patient-level linkage is possible (usually not due to privacy) or whether you’re doing population-level or statistical linkage.
Your Next Steps: Navigating the Data Enrichment Landscape
The pharmaceutical industry is fundamentally data-driven—but only if you can navigate the complex landscape of enriched healthcare datasets effectively.
The challenge most pharmaceutical companies face isn’t finding data providers—it’s determining which combination of capabilities, coverage, and analytical sophistication aligns with their strategic priorities. The enriched healthcare data market includes dozens of providers offering overlapping but distinct capabilities across aggregated claims data, synthetic patient cohorts, and advanced analytics platforms.
Understanding which specific data sources match your use cases requires deep market knowledge that most companies lack internally. The gap between understanding what enriched data can do theoretically and identifying which providers deliver the right combination of coverage, validation rigor, privacy compliance, and analytical tools for your specific needs is substantial.
Whether you’re a Data Scientist building predictive models, a Biostatistician preparing regulatory submissions, a Clinical Operations Lead optimizing trial design, or an HEOR professional building payer evidence—the decision framework should account for multiple dimensions: data recency, geographic and therapeutic coverage, synthetic data validation methodology, integration capabilities, compliance standards, and total cost of ownership.
Expert advisors who understand both your business objectives and the evolving real-world evidence ecosystem can accelerate your path to value while avoiding costly mismatches between requirements and provider capabilities.
Learn more about strategic approaches to aggregated and synthetic insurance data or explore how enriched datasets support pharma product launch analytics.
Ready to explore how enriched healthcare data can transform your research strategy? Understanding the landscape is the first step. Matching your specific requirements to the right combination of data sources, analytical capabilities, and domain expertise is the second—and that’s where professional guidance becomes critical. Contact us to discuss your analytical needs and explore strategic approaches to real-world intelligence that align with your business objectives.
Sources & References
- FDA. Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products. 2023. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug
- FDA. Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products. 2024. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-data-assessing-electronic-health-records-and-medical-claims-data-support-regulatory
- Chen RJ, et al. Harnessing the power of synthetic data in healthcare: innovation, application, and privacy. npj Digital Medicine. 2023. https://www.nature.com/articles/s41746-023-00927-3
- Hernandez M, et al. Synthetic data in health care: A narrative review. PLOS ONE. 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC9931305/
- Thorlund K, et al. Synthetic and External Controls in Clinical Trials – A Primer for Researchers. Therapeutic Innovation & Regulatory Science. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7218288/
- Jordon J, et al. Synthetic data in machine learning for medicine and healthcare. Nature Biomedical Engineering. 2021. https://www.nature.com/articles/s41551-021-00751-8
- Chaudhury S, et al. Synthetic Data in Healthcare and Drug Development: Definitions, Regulatory Frameworks, Issues. CPT: Pharmacometrics & Systems Pharmacology. 2025. https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/psp4.70021
- FDA. Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products. Draft Guidance. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/real-world-evidence-considerations-regarding-non-interventional-studies-drug-and-biological-products
- Murphy ML, et al. Synthetic data generation: a privacy-preserving approach to accelerate rare disease research. Frontiers in Digital Health. 2025. https://www.frontiersin.org/journals/digital-health/articles/10.3389/fdgth.2025.1563991/full
- Walonoski JA, et al. Protecting patient privacy in tabular synthetic health data: a regulatory perspective. npj Digital Medicine. 2025. https://www.nature.com/articles/s41746-025-02112-0
- Xu L, et al. Machine Learning for Synthetic Data Generation: A Review. arXiv. 2023. https://arxiv.org/html/2302.04062v8
- Goel S, et al. Addressing challenges with real-world synthetic control arms to demonstrate the comparative effectiveness of Pralsetinib in non-small cell lung cancer. Nature Communications. 2022. https://www.nature.com/articles/s41467-022-30908-1